demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 severe or critically
sarilumab low dose (200mg) Lescure ...

1 studies excluded by filtering options 0

4891 sarimulab phase 2 low dose, 0 013selection pending